PMDA Update: Its current situation
|
|
|
- Melvin Mervin Montgomery
- 6 years ago
- Views:
Transcription
1 PMDA Update: Its current situation and future direction Tatsuya Kondo, M.D. Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA), Japan 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam Netherlands Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners. 2
2 Contents PMDA Update; Its current situation and future direction 1. Organization 2. Activities iti in Medicinal i Products 3. Activities in Medical Devices 4. International Activities 3 PMDA s Safety Triangle Unique Three-pillar System Securing Nation s Safety Review Reduction in Risk Safety Continuous risk mitigation efforts Japanese Citizens Relief Relief measures for health damage caused by risk factors 4
3 PMDA Staff Size Administrative i ti part Safety Department 600 Review Department 500 Planned Major Changes Special Assistant for Chief Executive (Feb. 2012) Office of Review Innovation (Apr. 2012) Science Board (May 2012) of Center for Product Evaluation appointed (June 2012) Placed 2 Deputy Center s (June 2012) Reorganization of Office of Biologics (October 2012) 6
4 Organization Chart of PMDA Auditor Auditor Audit Office Chief Executive Executive Chief Relief Officer Chief Management Officer Chief Relief Officer Associate Center Associate Executive Associate Executive Center of Center for Product Evaluation Associate Center Deputy Center (for Cellular and Tissue-based Products) Associate Executive Deputy Center (for Medical Devices) Senior Executive Chief Safety Officer Offices of General Affairs / Office of Financial Management / Office of Planning and Coordination Office of Relief Funds Office of Regulatory Science Office of Standards and Guidelines Development Office of Review Administration Office of Review Management Office of International Programs / International Liaison Officers Office of New Drug Ⅰ - Ⅴ Office of Cellular and Tissue-based Products Office of Vaccines and Blood Products Office of OTC/Generic Drugs Office of Medical Devices Ⅰ-Ⅲ Office of Conformity Audit Principal Senior Scientist / Senior Scientists Office of GMP/QMS Inspection Office of Safety Ⅰ, Ⅱ 7 Contents PMDA Update; Its current situation and future direction 1. Organization 2. Activities iti in Medicinal i products 3. Activities in Medical devices 4. International Activities 8
5 Review Time for New Drugs Priority Review Products FY 2008 FY 2009 FY 2010 FY 2011 FY 2012 (As of Oct) FY2012 Target Total lreview Time (Month) Regulatory Review Time Applicant's time Standard Review Products FY 2008 FY 2009 FY 2010 FY 2011 FY 2012 (As of Oct) FY 2012 Target Total Review Time (Month) Regulatory Review Time Applicant's time Pharmaceutical Affairs Consultation on R&D Strategy Valley of Death -Short of funds, Knowledge on Regulation and development strategy Basic Research Pharmaceutical and Medical Devices candidates Strategic Consultation Quality Study Consultation on quality or toxicity study of biologics, cell-and tissue-based products Non- Clinical Study Clinical Trial Up to the level of fpoc studies Practical Use Innovative Products originated from Japan * Further studies are handled by the Regular Consultation Consultation on endpoints or sample size of early clinical trial 10
6 Science Board Science Board Committee members: External experts from Academia Not involved in the Review Process of individual products Committee Recommendation on 1. Review policy for innovative medical products 2. Development of guidelines 3. Regulatory Science Research 4. Personnel exchanges between PMDA and Academia 5. Election of External review experts 6. Improvements in the scientific aspects of review Subcommittee Deliberation on problems in each field Collaboration with PMDA working team (RS research, guideline development, etc.) Pharma- ceuticals Medical Devices Bio-based products Cell- & tissue- Based products 11 Promotion of personnel exchange human resource development NIHS Reviewers Researchers Universities and research institutions Medical Institutions Acquisition of innovative technologies Speed up and improve product review Outcome of researches Fostering of Regulatory Scientist Promotion of appropriate R & D Develop standards d and guidelines at early phase Facilitate practical application of innovative technologies Decrease drug /device lag
7 Improving Safety Measures Collection of Information Analysis Assessment of Safety measure effects New Risk management system Planning and Implementation of Safety measures Hypothesis Evaluation of hypothesis Crisis management Goal Prevention of serious drug safety-related crisis from Japan Effective encouragement of proper drug use. Ensuring credibility to post-market safety management system. Contents PMDA Update; Its current situation and future direction 1. Organization 2. Activities iti in Medicinal i products 3. Activities in Medical devices 4. International Activities 14
8 Medical Device Procedure Mt Material il Indication treatment Form diagnostic Medical Devices Regulation EU Japan US Brazil Canada Singapore Notified body certification (requirements depend on device classification) Class III, IV: Minister s approval Class II: Notified body certification Class I: Selfdeclaration Pre-market review Class III: PMA Approval Class II: 510(k) clearance, Class I: exemption Class III, IV: Registro to ANVISA Class II, III, IV: License from Health Canada Class I, II: Cadastro to ANVISA Class I: exemption Class B, C, D: Registration to HAS Class A: exemption Governmental approval/license Notified body review/certification Self declaration
9 Harmonization By Doing (HBD) Activity between Japan and USA to develop global clinical trialsand and address regulatory barriers that maybe impediments to timely device approvals. (since 2003) Steering Committee FDA MHLW/PMDA DCRI JAG AdvaMed JFMDA Guidance/Suggestion Report, Request Working Groups WG1:Global Cardiovascular Device Trials WG2: Study on Post market Registry WG3:Clinical Trials Infrastructure and Methodology WG4: Regulatory Convergence and Communication HBD Think Tank East 2013 (July 8 10, Tokyo, Japan) J-MACS Future partnership between Japan and the US (US Registry: INTERMACS)
10 Contents PMDA Update; Its current situation and future direction 1. Organization 2. Activities iti in Medicinal i products 3. Activities in Medical devices 4. International Activities 19 PMDA s international activities PMDA International Vision: PMDA EPOCH 1.Highest level of Excellence in Performance 2.Close Partnership with the Orient 3.Contribution to International Harmonization Strengthen bilateral and multilateral relationship Enhance human resource exchange / Cultivate employees with international minded and communication skills Improve International PR activities / information transmission
11 Dissemination of Information Review Report Safety Information PMDA Updates News Release And more 21 The First Indonesia-Japan Symposium Date: February 13, 2013 Venue: Jakarta, Indonesia Focus on: Pharmacovigilance and Good Distribution Practice Organizers: Pharmaceuticals and Medical Devices Agency (PMDA) Japan Pharmaceutical Manufacturers Association (JPMA) National Agency of Drug and Food Control (NADFC) Gabungan Perusahaan Farmasi Indonesia (GPFI) 22
12 3rd PMDA Training Seminar 2013 January Post-Marketing Safety & Relief Services 18 trainees from 6 countries: Korea, Taiwan, Indonesia, Singapore, Brazil, Ukraine Website: pmda 3rd_pmda_training_seminar.html 23 Trainings for individual Trainees Mid and short-term training May~July 2010: 2.5 months training for a SFDA reviewer Dec 2011: Medium-term Three weeks training training for three KFDA officials on general issues Feb 2012: One month training for TFDA (Taiwan FDA) officials on Medical Devices Mar 2013: One week training for Indonesian NADFC officials on pharmaceuticals Dr. Kondo with Trainees from KFDA Dr. Kondo with Trainees from Taiwan FDA 24
13 To Improve Public Health Review Safety Relief 25 Thank you for your attention! ti 26
Role and Vision of PMDA
Role and Vision of PMDA ~Promoting Global Public Health~ Taisuke Hojo Senior Executive Director Pharmaceutical and Medical Devices Agency (PMDA) 1 st Malaysia-Japan Symposium March 10 th, 2015 Today s
GCP Inspection by PMDA
2012 EU GCP Inspectors Working Group Workshop London, 12-14 November 2012 Practical Experience in GCP inspections, non EU/EEA countries GCP Inspection by PMDA Kazuko Natsui Inspector for GCP Inspection,
International trend on medical device regulatory convergence
International trend on medical device regulatory convergence Mari Shirotani, Ph.D. Division Director, Office of International Programs Pharmaceuticals and Medical Devices Agency (PMDA) 1st December, 2017
Direct Patient ADR reporting system in Japan. Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Direct Patient ADR reporting system in Japan Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan Disclaimer The views and opinions expressed in the following PowerPoint
Consideration on Global Harmonization
ICDRA Workshop I Consideration on Global Harmonization Oct. 25, 2012 Dr. Nobumasa Nakashima Director, Office of International Programs PMDA, Japan 1 Current Harmonization Activities ICH: International
Regional Alignment in Asia Pacific -
Regional Alignment in Asia Pacific - a Perspective from the Chair of the APEC Regulatory Harmonization Steering Committee (RHSC) Mike Ward Chair, APEC RHSC 3 rd Annual DIA Latin American Regulatory Conference
New Streams of Risk Management. Tomiko TAWARAGI Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA)
New Streams of Risk Management Tomiko TAWARAGI Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are
Forward looking approaches & its Experiences of PMDA's ATC
6 th Asia Partnership Conference of Pharmaceutical Associations, Tokyo, 5 th April 2017 Forward looking approaches & its Experiences of PMDA's ATC Junko Sato, PhD Office Director, Office of International
Progress Report in 2016
APAC Position Paper Progress Report in 2016 APAC RA-EWG Table of Contents INTRODUCTION 1 PROGRESS REPORT ON FOCUSED TOPIC(S) 3 IPMG (International Pharmaceutical Manufacturers Group) 3 JPMA (Japan Pharmaceutical
Why do we need an addendum to ICH E6?
Addendum to ICH E6 Hideaki Ui, Ph.D. Inspection Director Office of Non-clinical and Clinical Compliance Pharmaceuticals and Medical Devices Agency, Japan Disclaimer The views and opinions expressed in
Mid-term Targets of the Pharmaceuticals and Medical Devices Agency (PMDA) *(Provisional Translation)
Mid-term Targets of the Pharmaceuticals and Medical Devices Agency (PMDA) *(Provisional Translation) * This translation of the original Japanese text is for information purposes only (in the event of inconsistency,
PMDA EPOCH Toward 2020
PMDA International Vision PMDA EPOCH Toward 2020 As one of the world s top three medical products regulatory agencies comparable to its American and European counterparts, PMDA aims to: 1. Secure the highest
Pharmacovigilance in Japan and Risk Management Plans(RMP); Regulator Perspective
Pharmacovigilance in Japan and Risk Management Plans(RMP); Regulator Perspective Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan Disclaimer The views and opinions
Overview of ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
Overview of ICH June 2018 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH Legal notice Legal Notice This presentation is protected by copyright and
Trends in the development of regulatory systems by the example of ICH countries
Trends in the development of regulatory systems by the example of ICH countries Author: Pär Tellner, Member of ICH Management Committee (ICH MC), EFPIA * Date: 27/08/2018 * GMP conference, Kazan, Russia
International Medical Device Regulatory Harmonization. Reality or Fantasy?
International Medical Device Regulatory Harmonization Reality or Fantasy? Second Annual Medical Device Regulatory, Reimbursement and Compliance Congress Harvard University; 28-30 March 2007 M. Gropp; Medtronic,
Training, Site Selection and Human Subject Protection: Factors to Consider When Developing a Monitoring Plan
Training, Site Selection and Human Subject Protection: Factors to Consider When Developing a Monitoring Plan Cynthia F. Kleppinger, M.D. Senior Medical Officer Office of Scientific Investigations Office
Patient Survey Data Results: Reminder Preferences in Patient- Reported Outcomes Studies
Patient Survey Data Results: Reminder Preferences in Patient- Reported Outcomes Studies Mark Wade Director, Patient Focused Solutions Almac @AlmacClinTech Disclaimer The views and opinions expressed in
Quality Risk Management ICH Q9
Quality Risk Management ICH Q9 Executive summary for competent authorities and industry Disclaimer: This presentation includes the author s views on quality risk management theory and practice. The presentation
Observers Takuya Noro MHLW X X X Hideto Yokoi PMDA Advisor X X X Adriana Gamboa INFARMED X X X
Page 1 of 7 GHTF SG2 Meeting Location: INFARMED, Av. do Brasil, 53, 1749-004, LISBOA, PORTUGAL Date: 27-29 February 2008 Attendance: Name Organization Email 27/2 28/2 29/2 Miguel Antunes (MA) INFARMED
Additional Risk Minimisation and Burden: A CIOMS IX Perspective. Stephen Heaton, MD BayerHealthCare Member of CIOMS IX Working Group
Additional Risk Minimisation and Burden: A CIOMS IX Perspective Stephen Heaton, MD BayerHealthCare Member of CIOMS IX Working Group Disclaimer The views and opinions expressed in the following PowerPoint
ICH Regulators Forum. Dr Peter Arlett EU
Dr Peter Arlett EU International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use In this presentation ICH Regulators Forum: Background ICH Regulators
Current status on Adverse Event Reporting in Japan
Current status on Adverse Event Reporting in Japan Iku Mitta Safety Reports Management Division, Office of Safety I PMDA 1 Abbreviation ADR: Adverse Drug Reaction DB: Database EPPV:Early Post-Marketing
Addendum to ICH E6 (R2)
Addendum to ICH E6 (R2) Stephanie Shapley (US FDA) - Rapporteur Dr. Fergus Sweeney (EMA) - Regulatory Chair Date: December 15, 2015 International Council for Harmonisation of Technical Requirements for
Medical Innovation as a National Strategy
Medical Innovation as a National Strategy March 18, 2013 Hideaki Nakagaki Deputy General, Office of Healthcare Policy Cabinet Secretariat Provisional Translation 1 Establishment of Office of Healthcare
The place of the Certification procedure in 2017 in the EU regulatory framework and beyond. Prague, 19 September 2017
The place of the Certification procedure in 2017 in the EU regulatory framework and beyond Prague, 19 September 2017 Hélène BRUGUERA Head of the Certification Department, EDQM, Council of Europe CEPs in
Audit and Inspection
Audit and Inspection DIPLOMA COURSE on Research & Development of Products for Public Health Needs Thammasat University, Thailand 28 November, 2008 Dr. Allan K. Johansen, Roche Products Pty Limited, Australia
FDA Vision for Innovative Surveillance of Orthopedic Implants
FDA Vision for Innovative Surveillance of Orthopedic Implants Danica Marinac-Dabic, MD, PhD Director, CDRH Division of Epidemiology Head, FDA ICOR Initiative Total and Resurfacing Hip Systems: Post-Approval
Investigator Initiated-Sponsored Research (IISR)
Investigator Initiated-Sponsored Research (IISR) State of the Industry and the Need for Global Standards and Metrics Alexander Kostek and DeeAnn Tinjum Disclaimer The views and opinions expressed by the
A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program
A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry GOOD DISTRIBUTION PRACTICE FOR MEDICAL DEVICES IN SINGAPORE (GDPMDS)
ectd IV: It s Almost As Fun As Super Bowl XLIX DIA eregulatory and Intelligence Annual Conference Disclaimer
ectd IV: It s Almost As Fun As Super Bowl XLIX DIA eregulatory and Intelligence Annual Conference Mark Gray FDA/CBER Senior Project Manager 1 Disclaimer Views expressed in this presentation are those of
NANCI A. HAYWARD North Springs Drive Dunwoody, Georgia
1595 North Springs Drive Dunwoody, Georgia 30338 404-502-2823 nancihayward@thedragonflysolution.com Summary Over 25 years of team building, goal oriented management, and direct industrial experience using
Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan
Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan The views presented in this presentation are those of the author and should not be understood or quoted as being made
Changes to QSR. The table below provides a history of changes to FDA s Quality System Regulation (QSR)
Changes to QSR The table below provides a history of changes to FDA s Quality System Regulation (QSR) The citation is to the Federal R: the first number is the volume, FR indicates the Federal Register,
CURRICULUM VITAE. 23 December 1968, Varna, Bulgaria
CURRICULUM VITAE NAME: Milen Nikolaev Vrabevski, MD DATE/PLACE OF BIRTH: 23 December 1968, Varna, Bulgaria CONTACT DETAILS: South Side Business Centre 38, Maystor Aleksi Rilets Str., 5th fl. Res. Distr.
Real World Evidence in Europe
Real World Evidence in Europe Jessamy Baird, RWE Director Madrid, 20 th October 2014. BEFORE I BEGIN; DISCLAIMERS: Dual perspective: Pharmaceutical: I work for Lilly, but this presentation represents my
Software Regulation and Validation
Software Regulation and Validation Keiichiro Ozawa FUJIFILM Corporation 12/07/2016 4th Joint Conference of Taiwan and Japan on Medical Products Regulation 1 Agenda 0. Introduction 1. Qualification and
Take a Course of Action.
Take a Course of Action. When you choose RAPS Online University, you ll be on track to expand your regulatory knowledge and advance your career. Our comprehensive learning provides an immersive experience
Introduction of Saudi Arabia Medical Device Regulatory System Ali Al Dalaan Executive Director, SFDA AHWP TC Chair
Introduction of Saudi Arabia Medical Device Regulatory System Ali Al Dalaan Executive Director, SFDA AHWP TC Chair IMDRF Meeting. 20-22 March,2018. Shanghai, China Saudi Food & Drug Authority ) Drug Food
CQA Consultant of HVCC, Hilversum, the Netherlands. Coaching of auditors on various levels is an on-going activity.
CURRICULUM VITAE Name : Vlaskamp First name : Johanna Maria (Hanny) Title : BSc. Address : Vuurvlindermeent 14 1218 GZ Hilversum The Netherlands Phone : +31 (0)6 54995411 (mobile) Nationality : Dutch EDUCATION
A Competitiveness Policy for the Medical Technology Industry: Six Policy Proposals to Sustain American Leadership
A Competitiveness Policy for the Medical Technology Industry: Six Policy Proposals to Sustain American Leadership 1. Innovation in the life sciences must be a government priority. Since the ability of
ISO14155: 2011 Clinical investigation of medical devices for human subjects - Good Clinical Practice - ISO TC194 WG4 Madoka Murakami PMDA, Japan
ISO14155: 2011 Clinical investigation of medical devices for human subjects - Good Clinical Practice - ISO TC194 WG4 Madoka Murakami PMDA, Japan What is GCP? Good Clinical Practice (GCP) is an international
Standards and Medical Device Regulation Roundtable. Seoul South Korea. 21 October ASTM International
Standards and Medical Device Regulation Roundtable Seoul South Korea 21 October 2014 FDA s Use of Voluntary Consensus Standards Scott Colburn, Director CDRH Standards Program Office of the Center Director,
ANVISA - Enhancing marketing authorization of drugs and medical devices in accordance to the international best practices
ANVISA - Enhancing marketing authorization of drugs and medical devices in accordance to the international best practices Balbiana Verazez Sampaio Oliveira AGENDA 1. Strategic Plan 2016-2019 objectives
ICH ASSOCIATION 2016 ANNUAL REPORT
ICH ASSOCIATION 2016 ANNUAL REPORT International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH Secretariat, Chemin des Mines 9, 1202 Geneva, Switzerland Telephone:
Partnerships to Address Global Product Safety in Public Health. Dr. Katherine Bond November 18, 2014
Partnerships to Address Global Product Safety in Public Health Dr. Katherine Bond November 18, 2014 1 Presentation Overview I. FDA and Globalization I. FDA and PPPs: the Power of Collaboration II. FDA
Food Safety Capacity Building: The role of public private partnerships
Food Safety Capacity Building: The role of public private partnerships Paul Young, PhD Senior Director, Food and Environment Business Operations, Waters Corporation 2011 Waters Corporation 1 Background
MRC Funding and Translational Research. Dr Catriona Crombie
MRC Funding and Translational Research Dr Catriona Crombie Medical Research Council The Medical Research Council is dedicated to improving human health through the best scientific research. Its work, on
Role and Activities of NGO on Export Control. Hiroshi NAKAO Center For Information On Security Trade Control (CISTEC) JAPAN
Role and Activities of NGO on Export Control Hiroshi NAKAO Center For Information On Security Trade Control (CISTEC) JAPAN 1 Overview 1. Basic Requirements for Effective Export Controls 2. Role of our
Japanese Contribution for Disaster Management Support
Japanese Contribution for Disaster Management Support June 11 th 2010 Yasushi Horikawa Japan Aerospace Exploration Agency (JAXA) CONTENTS 1. Introduction 2. Activities of Sentinel Asia 3. Contribution
International Conference on Mediterranean Countries and EU opportunities Amman, Jordan, October 2012
International Conference on Mediterranean Countries and EU opportunities Amman, Jordan, 22-23 October 2012 KHCCBIO Supporting the Establishment of a Cancer Biobank for Jordan and its Neighboring Countries
September 2-3, 2013 Chengdu, China
Root Cause Investigations and Corrective Actions for GCP Compliance September 2-3, 2013 Chengdu, China Good Clinical Practice (GCP) is a compilation of best practices and quality standards to be applied
Early Feasibility Study: Expectation from Japanese Physicians Shigeru SAITO, MD, FACC Kamakura, JAPAN
Early Feasibility Study: Expectation from Japanese Physicians Shigeru SAITO, MD, FACC Kamakura, JAPAN HBD East 2017 Think Tank Meeting At National Institute of Global Health and Medicine Tokyo, Japan:
ICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY
ICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY 1. Opening Discussions The ICH Steering Committee (SC) meeting was chaired by the FDA. The meeting commenced with the provision of
Update on FDA-EMA QbD Pilot
Update on FDA-EMA QbD Pilot Presented by: Sharmista Chatterjee, PhD Branch Chief (Acting) Office of Process & Facility Office of Pharmaceutical Quality CDER, FDA Dolores Hernán, PhD Quality Office Specialized
Strategy for Partnerships And Innovation
Strategy for Partnerships And Innovation University of Manitoba, February 3, 2014 My Goals Today Discuss Interaction, Engage, Engage Plus grants Answer questions Interaction Grants Allow university researchers
Changing Requirements for Devices//Device Constituent Parts in Combination Products
Changing Requirements for Devices//Device Constituent Parts in Combination Products Dan Wozinski, RPH, MBA Sanofi Disclaimer The content and viewpoints of this presentation are mine alone and not those
The National Institute for Defense Studies (NIDS). Japan
The National Institute for Defense Studies (NIDS). Japan 1. Name of the Defense Institution The National Institute for Defense Studies (NIDS) (of Japan) 2. Location and point of contact (1) Location: 2-2-1
Guidance on Quality Management in Laboratories
Guidance on Quality Management in Laboratories series QULAITY IBMS 1 Institute of Biomedical Science Guidance on Quality Management in Laboratories As the UK professional body for biomedical science the
THE NATIONAL INVESTMENT IN RESEARCH. Professor Vicki Sara Chair, Australian Research Council
THE NATIONAL INVESTMENT IN RESEARCH Professor Vicki Sara Chair, Australian Research Council National Innovation System Public Research Institutes Knowledge Creativity Flow Private Enterprise Universities
Determining and Reporting Adverse Events vs. Product Complaints
Determining and Reporting Adverse Events vs. Product Complaints Pharma Perspective: Jacqueline Grissinger Director, Office of Consumer Medical Safety Johnson & Johnson Medical Device Perspective: Lisa
Portland, Oregon, USA (Portland Marriott Downtown Waterfront Hotel)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GLOBAL COOPERATION GROUP MEETING REPORT TUESDAY JUNE 3, 2008 Portland, Oregon, USA
SYNERGY TRANSLATIONAL RESEARCH METHODS INSTITUTE
1 The Dartmouth Clinical and Translational Science Institute SYNERGY TRANSLATIONAL RESEARCH METHODS INSTITUTE (schedule subject to change) Purpose: The purpose of the one-week Institute is to provide an
Frank Fowlie. Office of the Ombudsman. Remarks at Marrakesh Public Forum. June 28, Check against delivery
Frank Fowlie Office of the Ombudsman Remarks at Marrakesh Public Forum June 8, 006 Check against delivery Frank Fowlie 6/8/006 Check against Delivery Wellington Remarks 5:7: AM Mr. Chairman, Vint Cerf,
International Collaborations JSPS. Toward Overcoming Chemical Hazards in African Countries
c o l u m n Selected under the Core-to-Core Program (B. Asia-Africa Science Platforms) Toward Overcoming Chemical Hazards in African Countries Stepping forward, into science s world Program Title: Establishment
Public Health Subcommittee
Public Health Subcommittee Decision Brief: Improving Defense Health Program Medical Research Processes Defense Health Board June 26, 2017 1 Overview Tasking Membership Timeline Findings & Recommendations
Cooperation of Japan with ASEAN
Cooperation of Japan with ASEAN The Third ASEAN+Japan TELSOM August 21, 2007 Siem Reap, Kingdom of Cambodia Toru NAKAYA Director for International Cooperation Ministry of Internal Affairs and Communications,
Changes to the Hitachi Scholarship Programs
July 3, 2017 Changes to the Hitachi Scholarship Programs 2017 Programs The Hitachi Scholarship ①Doctoral Program 2018 The Hitachi Scholarship ① Doctoral Program (Support for current scholars will continue
Eligibility Criteria for NIHR Clinical Research Network Support
Eligibility Criteria for NIHR Clinical Research Network Support December 2017 Title: Eligibility Criteria for NIHR Clinical Research Network Support Author: Authored by NIHR Clinical Research Network.
<Insert Picture Here> Some Background and What You Should Know and Do Now to Prepare
1 E2B (R3): Some Background and What You Should Know and Do Now to Prepare The following is intended to outline our general product direction. It is intended for information purposes
Regional Update ASEAN PPWG
Regional Update ASEAN PPWG by Yuppadee JAVROONGRIT, Ph.D. Co-Chair of ACCSQ/PPWG, ASEAN Drug Control Division, ThaiFDA, Thailand The ICH-Global Cooperation Group Meeting Yokohama Royal Park Hotel, Yokohama,
Training components for GCP. inspectors in PMDA. Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA
Training components for GCP inspectors in PMDA Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA Content 1. Conformity inspection in the training program for newcomers to PMDA 2. The training
FINAL STATUS DOCUMENT
GHTF/SG2/N68R3: 2005 FINAL STATUS DOCUMENT Global Harmonization Task Force Title: Summary of Current Requirements for Where to Send Adverse Event Reports. Authoring Group: GHTF Study Group 2 Endorsed by:
AST Research Network Career Development Grants: 2019 Faculty Development Research Grant
AST Research Network Career Development Grants: 2019 Faculty Development Research Grant The application deadline is 11:59 pm Pacific Standard Time on Wednesday, November 1, 2018. A limited number of grants
EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
UNCLASSIFIED. R-1 ITEM NOMENCLATURE PE F: International Activities
Exhibit R-2, RDT&E Budget Item Justification: PB 2012 Air Force DATE: February 2011 COST ($ in Millions) FY 2013 FY 2014 FY 2015 FY 2016 Air Force Page 1 of 8 R-1 Line Item #106 Cost To Complete Cost Program
RULES for the. EUROPEAN HEART RHYTHM ASSOCIATION (EHRA) (a Registered Branch of the ESC)
RULES for the EUROPEAN HEART RHYTHM ASSOCIATION (EHRA) (a Registered Branch of the ESC) INTERNATIONAL TRAINING FELLOWSHIP PROGRAMME For clinical electrophysiology with emphasis on catheter ablation Chair:
APEC Subcommittee on Standards and Conformance
APEC Subcommittee on Standards and Conformance 2011 Projects and Activities Presented By Jennifer Stradtman U.S. Representative to the SCSC Office of the ITA Standards Liaison U.S. Department of Commerce
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
Completing E2B(R3) Compliance in Total Safety 7
@ris global Let s Innovate for Life 2016 Completing E2B(R3) Compliance in Total Safety 7 Author: Christian Schmitz-Moormann, Senior Director, Leading Practices Mark Loudon Senior Director, Risk Management
Activities of Korea Water Forum for Sustainable Youth Movement : Asia-Pacific Youth Parliament for Water
Activities of Korea Water Forum for Sustainable Youth Movement : Asia-Pacific Youth Parliament for Water 5. Nov. 03 Ms. Jiyeon LEE, Project Officer Korea Water Forum Lifelong Water Education Programs For
Policy Recommendation of the AEM-MITI's Working Group on Economic Cooperation in Cambodia, Laos and Myanmar Phnom Penh, 23 August 1996
Policy Recommendation of the AEM-MITI's Working Group on Economic Cooperation in Cambodia, Laos and Myanmar Phnom Penh, 23 August 1996 At the 5th meeting of the Working Group in Phnom Penh on August 23,1996,
Patient Registries Initiative Background, Achievements, Next steps
Patient Registries Initiative Background, Achievements, Next steps 21 November 2017 ENCePP Plenary meeting Presented by Xavier Kurz, Surveillance & Epidemiology Service, European Medicines Agency An agency
Post Market Surveillance (PMS): National Competent Authority Report (NCAR) Exchange Programme under IMDRF
Post Market Surveillance (PMS): National Competent Authority Report (NCAR) Exchange Programme under IMDRF SAMED Conference, 2-3/12/2015 Dr Isabelle Demade What is IMDRF? Introduction - established in 2011
Characteristics of Specialty Occupation Workers (H-1B): Fiscal Year 2003
U.S. Department of Homeland Security Office of Immigration Statistics Characteristics of Specialty Occupation Workers (H-1B): Fiscal Year 2003 Issued July 2004 Report Mandated by Public Law 105-277, Division
Hitachi Scholarship Research Support Program for 2018 Application Guidelines
Hitachi Scholarship Research Support Program for 2018 Application Guidelines The Hitachi Global Foundation (hereinafter referred to as the Foundation ) offers Research Support Grants (hereinafter referred
AST Research Network Career Development Grants: 2019 Fellowship Research Grant
AST Research Network Career Development Grants: 2019 Fellowship Research Grant The application deadline is 11:59 pm Pacific Standard Time on Wednesday, November 1, 2018. A limited number of grants are
Introduction to China CDISC Coordinating Committee (C3C) February 2014
Introduction to China CDISC Coordinating Committee (C3C) February 2014 Outline Regulatory history of study data in China CDISC application and history in China China CDISC coordinating committee (C3C)
International Trend on Medical Device Regulatory Convergence
International Trend on Medical Device Regulatory Convergence 5th Joint Conference of Taiwan and Japan on Medical Products Regulation December 1, 2017 Taipei 1 Content Overview of major international harmonization
FINAL STATEMENT BY THIRD APEC HIGH LEVEL MEETING ON HEALTH AND THE ECONOMY
FINAL STATEMENT BY THIRD APEC HIGH LEVEL MEETING ON HEALTH AND THE ECONOMY The third APEC High Level Meeting on Health and the Economy (HLM3) was held in Nusa Dua, Bali, Indonesia, on 24-25 September 2013.
BRISTOL-MYERS SQUIBB DATA SHARING INDEPENDENT REVIEW COMMITTEE (IRC) CHARTER
BRISTOL-MYERS SQUIBB DATA SHARING INDEPENDENT REVIEW COMMITTEE (IRC) CHARTER Charter Effective Date: October 13, 2017 Release v2.0 Page 1 of 6 Introduction This Charter describes the roles and responsibilities
Life Sciences in the Czech Republic.
Life Sciences in the Czech Republic www.czechinvest.org Czech Life Sciences at a Glance World-class academic community and research base with a strong commitment to partnering with industry Established
SPP and Eco-labelling: The global contribution of UNEP
1 SPP and Eco-labelling: The global contribution of UNEP International Symposium Green Public Procurement and Eco-labelling toward Sustainable Consumption and Production in the ASEAN region Tokyo, 11 December
FDA Reauthorization Act of 2017 (FDARA)
FDA Reauthorization Act of 2017 (FDARA) April 4, 2018 PRESENTED BY: Jessica Ringel Counsel FDA & Life Sciences Practice Group King & Spalding LLP (202) 626-9259 jringel@kslaw.com FDA Reauthorization Act
European Patients Academy (EUPATI) Update
European Patients Academy (EUPATI) Update EMA meeting with patient/consumer organisations 11 Dec 2013 Maria Mavris EURORDIS // EUPATI WP4 Co-Lead For patient-centric medicines R&D and to contribute to
Introducing Horizon 2020
Introducing Horizon 2020 Dr Martin Grabert 17 September 2014 1 A short history of the EC Framework Programs It all started with a book Le Défi Américain ( The American Challenge, 1967) by Jean-Jacques
Safe medication practice what can we learn from root cause analysis and related methods?
Safe medication practice what can we learn from root cause analysis and related methods? Dr David Gerrett, Senior Pharmacist Patient Safety NHS Improvement Information Day on Medication Errors 20 October
Sigma Theta Tau International: Providing Global Leadership. Cathy Catrambone, PhD, RN, FAAN President-Elect Sigma Theta Tau International
Sigma Theta Tau International: Providing Global Leadership Cathy Catrambone, PhD, RN, FAAN President-Elect Sigma Theta Tau International Objectives 1. Describe how STTI addresses global leadership challenges.
ETH Zurich Cooperation with China
ETH Zurich Cooperation with China Anders Hagström, Director International Educational Affairs Outline About ETH Zurich Science and Technology in China ETH Zurich s links with China Sino-Swiss Science and
Rules and Procedures for IMI Calls for proposals. IMI Webinar 17 July 2017
Rules and Procedures for IMI Calls for proposals IMI Webinar 17 July 2017 Outline 1. Introducing IMI 2. Participation rules 3. Funding rules 4. Intellectual property rules 5. From Call to grant award 6.